Oxular’s CMO, Friedrich Asmus, MD, spoke at the Dry AMD Therapeutic Development conference in Boston, presenting Oxular’s “Routine Suprachoroidal Drug Administration and it’s role in Intermediate AMD/GA Therapies” You can view his presentation here
OXFORD, UK – November 7, 2022 – Oxular Limited, a clinical-stage retinal therapeutics company developing long-lasting targeted treatments for retinal disorders to improve patients’ vision, today announced the appointment of James “Jim” Jogerst as chief business officer, who will lead the company’s business development strategy, and oversee its current and planned strategic partnerships. Mr. Jogerst …
Oxular is thrilled to sponsor ISU 2022 in Utrecht, The Netherlands, and introduce the Oxulumis® suprachoroidal microcatheter to leading uveitis specialists. Together with Marc D. de Smet, we will host a series of skill transfer labs and provide hands-on instruction for routine suprachoroidal drug administration using Oxulumis®. We look forward to seeing you all there.
Christina is co-founder and Managing Director of V-Bio Ventures. With more than 20 years of investment experience in European venture capital, Christina was previously a partner with Forbion Capital Partners (formerly ABN AMRO Capital) where she led and managed a series of successful biotech investments since 2001. Christina currently serves on the boards of Confo …
Rafiq is the CEO of Complement Therapeutics, a life sciences company aiming to develop the next generation of complement medicines. Rafiq has pursued a successful career in the pharmaceutical industry globally, including senior positions in ophthalmology with Bayer and Novartis. Most recently as Senior Vice President and Global Head of Ophthalmology at Bayer, Rafiq grew …
Dina is a partner with NeoMed Management, and Advisor to Omega Funds. She has been investing in the private equity and venture capital healthcare industry in Europe and the US since 2001. Previously at 3i in London and Index Ventures in Geneva, Dina’s successful investments include Endosense, EUSA Pharma, Novexel, and Wilson Therapeutics. Dina serves …
Thomas is co-founder, CEO, and a Board member of Oxular. He is an experienced and successful entrepreneur who has helped to build previous private-equity-backed ventures. He was formerly co-founder and CEO of ophthalmic pharmaceutical company Aciex Therapeutics, where he brought its lead program to NDA and led the company through a successful M&A exit. His …
Our Site
General Contact
Magdalen Centre
1 Robert Robinson Avenue
Oxford, OX4 4GA, UK
Media Contact
Ben Atwell / Alex Davis
FTI Consulting
London
Limited company registered in England and Wales (Registration No. 09331313) VAT No. GB 244 5883 81
Copyright Oxular Limited
Website designed by Emerald Grove Studio
Website built by THRH Consulting
Follow us on
Limited company registered in England and Wales (Registration No. 09331313) VAT No. GB 244 5883 81
Copyright Oxular Limited
Website designed by Emerald Grove Studio
Website built by THRH Consulting